Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Agios Pharmaceuticals, Inc. (AGIO)

Pharmaceutical Preparations

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

88 SIDNEY STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/24/2013

Market Cap

2,572,990,448

Shares Outstanding

55,890,000

Weighted SO

55,891,284

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

MREO --.--%

BPMC --.--%

DAWN --.--%

BMRN --.--%

IDYA --.--%

ANAB --.--%

MGTX --.--%

KROS --.--%

FIXX --.--%

Beta

0.7830

Last Div

0.0000

Range

19.8-50.35

Chg

0.3150

Avg Vol

739483

Mkt Cap

2572990448

Exch

NASDAQ

Country

US

Phone

617 649 8600

DCF Diff

56.2108

DCF

-11.1358

Div Yield

0.0000

P/S

82.1884

EV Multiple

-6.3713

P/FV

3.8893

Div Yield %

0.0000

P/E

-7.0394

PEG

-0.4639

Payout

0.0000

Current Ratio

10.0919

Quick Ratio

9.7098

Cash Ratio

1.3493

DSO

43.8616

DIO

1136.8907

Op Cycle

1180.7523

DPO

476.6135

CCC

704.1387

Gross Margin

0.7545

Op Margin

-12.9388

Pretax Margin

-11.6569

Net Margin

-11.6569

Eff Tax Rate

0.0201

ROA

-0.4721

ROE

-0.4705

ROCE

-0.5702

NI/EBT

1.0000

EBT/EBIT

0.9009

EBIT/Rev

-12.9388

Debt Ratio

0.0836

D/E

0.0978

LT Debt/Cap

0.0687

Total Debt/Cap

0.0891

Int Coverage

0.0000

CF/Debt

-4.7445

Equity Multi

1.1704

Rec Turnover

8.3216

Pay Turnover

0.7658

Inv Turnover

0.3211

FA Turnover

0.5092

Asset Turnover

0.0405

OCF/Share

-5.3974

FCF/Share

-5.7214

Cash/Share

10.0329

OCF/Sales

-9.7932

FCF/OCF

1.0600

CF Coverage

-4.7445

ST Coverage

-19.3308

CapEx Coverage

-16.6605

Div&CapEx Cov

-16.6605

P/BV

3.8893

P/B

3.8893

P/S

82.1884

P/E

-7.0394

P/FCF

-7.9172

P/OCF

-8.3790

P/CF

-8.3790

PEG

-0.4639

P/S

82.1884

EV Multiple

-6.3713

P/FV

3.8893

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 08, 17:40 Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat MarketWatch Jan 03, 10:10 Nvidia and other stocks "approaching the trough of disillusionment" over GenAI MarketWatch Jan 03, 08:55 Nvidia and other stocks "approaching the trough of disillusionment" over GenAI GlobeNewswire Inc. Jan 03, 06:30 Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 19:00 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Revenue Product Segmentation